Compare · SMTI vs STE
SMTI vs STE
Side-by-side comparison of Sanara MedTech Inc. (SMTI) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SMTI and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.50B, about 101.3x SMTI ($202.4M).
- Over the past year, SMTI is down 23.2% and STE is down 13.5% - STE leads by 9.7 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 10 for SMTI).
- STE has more recent analyst coverage (16 ratings vs 5 for SMTI).
- Company
- Sanara MedTech Inc.
- STERIS plc (Ireland)
- Price
- $22.24+1.46%
- $210.04-1.01%
- Market cap
- $202.4M
- $20.50B
- 1M return
- +16.56%
- -1.87%
- 1Y return
- -23.18%
- -13.48%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 39
- Recent ratings
- 5
- 16
Sanara MedTech Inc.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. It also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers; and PULSAR II Advanced Wound Irrigation System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest SMTI
- Director Tanzberger Eric D was granted 5,308 shares, increasing direct ownership by 30% to 22,966 units (SEC Form 4)
- Director Major Eric D was granted 4,846 shares, increasing direct ownership by 52% to 14,232 units (SEC Form 4)
- Director Ortwein Sara N was granted 4,616 shares, increasing direct ownership by 22% to 25,415 units (SEC Form 4)
- Director Nixon Ronald T was granted 4,154 shares, increasing direct ownership by 6% to 68,196 units (SEC Form 4)
- Director Desutter Robert Andrew was granted 5,539 shares, increasing direct ownership by 24% to 28,740 units (SEC Form 4)
- Director Salamone Ann Beal was granted 4,154 shares, increasing direct ownership by 18% to 26,858 units (SEC Form 4)
- Director Mack Roszell Iii was granted 5,308 shares, increasing direct ownership by 32% to 21,842 units (SEC Form 4)
- Director Myers Keith G was granted 4,385 shares, increasing direct ownership by 89% to 9,325 units (SEC Form 4)
- Sanara MedTech Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Chief Executive Officer Yon Seth D covered exercise/tax liability with 3,852 shares, decreasing direct ownership by 3% to 109,546 units (SEC Form 4) (for tax liability)
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)